# OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder

> **NCT01945489** · PHASE4 · COMPLETED · sponsor: **Allergan** · enrollment: 254 (actual)

## Conditions studied

- Overactive Bladder

## Interventions

- **BIOLOGICAL:** onabotulinumtoxinA
- **DRUG:** Normal saline

## Key facts

- **NCT ID:** NCT01945489
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-28
- **Primary completion:** 2016-05-24
- **Final completion:** 2017-01-05
- **Target enrollment:** 254 (ACTUAL)
- **Last updated:** 2017-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01945489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01945489, "OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01945489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*